Volume 10 Number 2 2026
Engineering Blood-Brain Barrier Penetrant Delivery Systems for Glioblastoma Mechanistic Barriers, Platform Innovation, and the Long Road to the Clinic
Long Chiau Ming 1*, Ong Khang Wei 2, Nurul Dayana Binti Mahizir 2
Integrative Biomedical Research 10 (2) 1-8 https://doi.org/10.25163/biomedical.10210937
Submitted: 27 July 2026 Revised: 14 September 2026 Accepted: 23 September 2026 Published: 25 September 2026
Glioblastoma (GBM) remains, despite three decades of trial-and-error refinement of the Stupp protocol, a disease that most patients do not survive beyond fifteen months. This review asks a fairly narrow but stubborn question: why do so many pharmacologically promising agents, effective in a dish, fail once they must cross the blood–brain barrier (BBB) and reach the infiltrative rim of a real tumor? We synthesize evidence across four interlocking domains. First, we examine the physiological and biophysical barriers, from tight-junction–sealed endothelium to the elevated interstitial fluid pressure that opposes convective drug movement Second, we catalogue the nanomedicine platforms, lipid, polymeric, albumin-based, inorganic, and biomimetic, that have been engineered to outmaneuver these obstacles. Third, we consider receptor-mediated transcytosis and a case study, the Dendrobium-derived bibenzyl TDB, which appears to suppress dual mTORC1/mTORC2 signaling, trigger apoptosis, and resensitize glioma cells to temozolomide. Fourth, we turn to physical and locoregional strategies, focused ultrasound, convection-enhanced delivery, intra-arterial infusion, and intranasal transport, several of which have now produced encouraging early-phase clinical signals. Rather than presenting these as separate success stories, we argue, perhaps more cautiously than earlier reviews, that their common failure mode is the same: drug reaches the enhancing core but not the non-enhancing margin where recurrence begins. We close by outlining what a more reproducible translational pipeline, biomarker-guided, spatially validated, might look like going forward.
Keywords: glioblastoma; blood-brain barrier; blood-tumor barrier; nanomedicine; receptor-mediated transcytosis; focused ultrasound; TDB; translational bottlenecks
Anwer, M. S., Abdel-Rasol, M. A., & El-Sayed, W. M. (2025). Emerging therapeutic strategies in glioblastoma: Drug repurposing, mechanisms of resistance, precision medicine, and technological innovations. Clinical and Experimental Medicine, 25(1), 117. https://doi.org/10.1007/s10238-025-01517-w
Arroyo, J. F., & Leon-Rojas, J. E. (2026). The glymphatic–immune axis in glioblastoma: Mechanistic insights and translational opportunities. International Journal of Molecular Sciences, 27(2), 928. https://doi.org/10.3390/ijms27020928
Arvanitis, C. D., Ferraro, G. B., & Jain, R. K. (2020). The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nature Reviews Cancer, 20(1), 26–41. https://doi.org/10.1038/s41568-019-0205-x
Aung, H. M., Wattanathamsan, O., Sanookpan, K., Hongprasit, A., Muangnoi, C., Phumsuay, R., Rojpitikul, T., Sritularak, B., Bunlue, T., Chantaravisoot, N., Oliva, C. R., Griguer, C. E., & Buranasudja, V. (2025). A bibenzyl from Dendrobium pachyglossum exhibits potent anti-cancer activity against glioblastoma multiforme. Antioxidants, 14(10), 1212. https://doi.org/10.3390/antiox14101212
Buist, D., van der Weide, H., Bergink, S., & Chiu, R. (2025). A theoretical framework for ligand-functionalised magnetic lipid nanoparticles in glioblastoma therapy. Cancers, 17(24), 3905. https://doi.org/10.3390/cancers17243905
Burkhardt, J. K., Riina, H., Shin, B. J., Christos, P., Kesavabhotla, K., Hofstetter, C. P., Tsiouris, A. J., & Boockvar, J. A. (2012). Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: Progression-free survival and overall survival. World Neurosurgery, 77(1), 130–134. https://doi.org/10.1016/j.wneu.2011.05.056
Castro, L. M., Neves, A. R., Vivès, E., Boisguérin, P., Sousa, Â., & Costa, D. (2026). Peptide-based nanocomplexes enable transferrin-mediated uptake and p53-driven antitumor activity in 2D and 3D glioblastoma models. International Journal of Molecular Sciences, 27(15), 6857. https://doi.org/10.3390/ijms27156857
Coronado, L., Lakey-Beitia, J., Pecchio, M., Ng, M. G., Correa, R., Samudio-Ríos, G., Cruz-Mora, J., Fuentes, A. L., Rao, K. S. J., & Spadafora, C. (2025). Insights into the structural patterns in human glioblastoma cell line SF268 activity and ADMET prediction of curcumin derivatives. Pharmaceutics, 17(8), 968. https://doi.org/10.3390/pharmaceutics17080968
D'Amico, R. S., Aghi, M. K., Vogelbaum, M. A., & Bruce, J. N. (2021). Convection-enhanced drug delivery for glioblastoma: A review. Journal of Neuro-Oncology, 151(3), 415–427. https://doi.org/10.1007/s11060-020-03408-9
De Sousa-Coelho, A. L., Solakovic, B., Bento, A. D., & Fernandes, M. T. (2025). Drug repurposing for targeting cancer stem-like cells in glioblastoma. Cancers, 17(18), 2999. https://doi.org/10.3390/cancers17182999
Donnini, F., Minniti, G., Rubino, G., Battaglia, G., Pastina, P., Carfagno, T., Vannini, M., Mazzei, M. A., & Tini, P. (2025). Glia between resistance and radiotoxicity in glioblastoma: Mechanisms and translational perspectives—A narrative review. Neuroglia, 6(4), 44. https://doi.org/10.3390/neuroglia6040044
Dréan, A., Rosenberg, S., Lejeune, F.-X., Goli, L., Nadaradjane, A. A., Guehennec, J., Schmitt, C., Verreault, M., Bielle, F., Mokhtari, K., et al. (2018). ATP binding cassette (ABC) transporters: Expression and clinical value in glioblastoma. Journal of Neuro-Oncology, 138(3), 479–486. https://doi.org/10.1007/s11060-018-2819-3
Dynarowicz, K., Aebisher, D., Tylutki, J., Kozak, N., Kawczyk-Krupka, A., & Bartusik-Aebisher, D. (2026). Small particles, big impact: Inorganic nanotechnology for glioblastoma. Molecules, 31(2), 565. https://doi.org/10.3390/molecules31020565
Fayed, S., Amer, S., Badawy, M., Bou Malhab, L., Omran, N., Khoder, G., Ghemrawi, R., Haider, M., Hamoudi, R., & Harati, R. (2026). The role of CRISPR and its therapeutic applications in glioblastoma. International Journal of Molecular Sciences, 27(4), 2008. https://doi.org/10.3390/ijms27042008
Ferreira, C., Sarmento, B., & Martins, C. (2025). In vitro models of the interplay between glioblastoma and blood-brain barrier for stratifying drug efficacy. Advanced Drug Delivery Reviews, 227, 115702. https://doi.org/10.1016/j.addr.2025.115702
Ghosh, A., Majie, A., Karmakar, V., Chatterjee, K., Chakraborty, S., Pandey, M., Jain, N., Roy Sarkar, S., Nair, A. B., & Gorain, B. (2024). In-depth mechanism, challenges, and opportunities of delivering therapeutics in brain using intranasal route. AAPS PharmSciTech, 25(5), 96. https://doi.org/10.1208/s12249-024-02812-7
Grzegorzewski, J., Michalak, M., Woloszczuk, M., Bulicz, M., & Majchrzak-Celinska, A. (2025). Nanotherapy of glioblastoma—Where hope grows. International Journal of Molecular Sciences, 26(5), 1814. https://doi.org/10.3390/ijms26051814
Guo, Y., You, H., Li, Y., Zhou, Z., Tian, Z., Jiang, C., & Sun, T. (2025). Polymer-engineered PROTAC nanovehicles amplify synergistic effects with temozolomide by BRD4 degradation. Biomaterials Science, 13(18), 5001–5016. https://doi.org/10.1039/D5BM00512A
Gupta, T., Sahoo, R. K., Singh, H., Katke, S., Chaurasiya, A., & Gupta, U. (2023). Lipid-based nanocarriers in the treatment of glioblastoma multiforme (GBM): Challenges and opportunities. AAPS PharmSciTech, 24(4), 102. https://doi.org/10.1208/s12249-023-02558-4
Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024). Receptor-mediated transcytosis for brain delivery of therapeutics: Receptor classes and criteria. Frontiers in Drug Delivery, 4, 1360302. https://doi.org/10.3389/fddsv.2024.1360302
Hasanpour-Segherlou, Z., Alikhani, A., Bertola, L., Rupp, C., Haghighi, M., Kim, J., Rawson, C., Baloi, A., Hosseini, F., Pahlevani, M., & Lucke-Wold, B. (2026). Integrating endovascular drug delivery into the therapeutic landscape of glioblastoma. Cancers, 18(4), 2278. https://doi.org/10.3390/cancers18042278
Iv, M., Naya, L., Sanan, S., Van Buskirk, S. L., Nagpal, S., Thomas, R. P., Recht, L. D., & Patel, C. B. (2024). Tumor treating fields increases blood-brain barrier permeability and relative cerebral blood volume in patients with glioblastoma. The Neuroradiology Journal, 37(1), 107–118. https://doi.org/10.1177/19714009231182245
Jnaidi, R., Almeida, A. J., & Gonçalves, L. M. (2020). Solid lipid nanoparticles and nanostructured lipid carriers as smart drug delivery systems in the treatment of glioblastoma multiforme. Pharmaceutics, 12(9), 860. https://doi.org/10.3390/pharmaceutics12090860
Joyce, P., Allen, C. J., Alonso, M. J., Ashford, M., Bradbury, M. S., Germain, M., Kavallaris, M., Langer, R., Lammers, T., Peracchia, M. T., et al. (2024). A translational framework to DELIVER nanomedicines to the clinic. Nature Nanotechnology, 19(11), 1597–1611. https://doi.org/10.1038/s41565-024-01754-7
Juanes-Gusano, D., Fernández-Roldán, B., Coveñas, R., & Hijazi, M. (2026). Targeting kinase signaling in glioblastoma: Structural optimization, blood–brain barrier dynamics and combinatorial translational strategies. International Journal of Molecular Sciences, 27(13), 6590. https://doi.org/10.3390/ijms27136590
Karlo, W., Dlugon, M., Gutowska, I., Wszolek, A., & Zwierello, W. (2026). Targeting ferroptosis in glioblastoma: Molecular mechanisms, tumor microenvironment, and therapeutic opportunities. Cancers, 18(4), 2018. https://doi.org/10.3390/cancers18042018
Kim, Y., Armstrong, T. S., Gilbert, M. R., & Celiku, O. (2023). A critical analysis of neuro-oncology clinical trials. Neuro-Oncology, 25(9), 1658–1671. https://doi.org/10.1093/neuonc/noad073
Lindner, M., Lisinska, D., Kedzierska, A., & Majchrzak-Celinska, A. (2026). Bromodomain-containing protein 4 (BRD4) in glioblastoma: Pathophysiological roles and emerging therapeutic strategies. International Journal of Molecular Sciences, 27(5), 2268. https://doi.org/10.3390/ijms27052268
Louis, D. N., Perry, A., Wesseling, P., Brat, D. J., Cree, I. A., Figarella-Branger, D., Hawkins, C., Ng, H. K., Pfister, S. M., Reifenberger, G., Soffietti, R., von Deimling, A., & Ellison, D. W. (2021). The 2021 WHO classification of tumors of the central nervous system: A summary. Neuro-Oncology, 23(8), 1231–1251. https://doi.org/10.1093/neuonc/noab106
Loushambam, B., Shimray, M. M. K., Khangembam, R., Krishnaswami, V., & Vijayaraghavalu, S. (2025). Nanomedicine-based advances in brain cancer treatment—A review. Neuroglia, 6(3), 28. https://doi.org/10.3390/neuroglia6030028
Martins, C., Araújo, M., Malfanti, A., Pacheco, C., Smith, S. J., Ucakar, B., Rahman, R., Aylott, J. W., Préat, V., & Sarmento, B. (2023). Stimuli-responsive multifunctional nanomedicine for enhanced glioblastoma chemotherapy augments multistage blood-to-brain trafficking and tumor targeting. Small, 19(24), 2300029. https://doi.org/10.1002/smll.202300029
Mason, W. P. (2015). Blood-brain barrier-associated efflux transporters: A significant but underappreciated obstacle to drug development in glioblastoma. Neuro-Oncology, 17(9), 1181–1182. https://doi.org/10.1093/neuonc/nov147
Mishra, P., Gupta, P., Markowska, A., Ghavami, S., Markowski, J., & Los, M. J. (2026). Advancements in drug delivery systems in glioblastoma therapy. International Journal of Molecular Sciences, 27(5), 2298. https://doi.org/10.3390/ijms27052298
Mokarram, N., Case, A., Hossainy, N. N., Lyon, J. G., MacDonald, T. J., & Bellamkonda, R. (2025). Device-assisted strategies for drug delivery across the blood-brain barrier to treat glioblastoma. Communications Materials, 6(1), 5. https://doi.org/10.1038/s43246-024-00712-4
Neuwelt, E. A., Abbott, N. J., Abrey, L., Banks, W. A., Blakley, B., Davis, T., Engelhardt, B., Grammas, P., Nedergaard, M., Nutt, J., et al. (2008). Strategies to advance translational research into the blood-brain barrier. The Lancet Neurology, 7(1), 84–96. https://doi.org/10.1016/S1474-4422(07)70326-5
Noorani, I., & de la Rosa, J. (2023). Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nature Communications, 14, 5909. https://doi.org/10.1038/s41467-023-41591-1
Ozarowski, M., Karpinski, T. M., Czerny, B., Kaminski, A., & Seremak-Mrozikiewicz, A. (2025). Plant alkaloids as promising anticancer compounds with blood–brain barrier penetration in the treatment of glioblastoma: In vitro and in vivo models. Molecules, 30(7), 1561. https://doi.org/10.3390/molecules30071561
Power, E. A., Rechberger, J. S., Gupta, S., Schwartz, J. D., Daniels, D. J., & Khatua, S. (2022). Drug delivery across the blood-brain barrier for the treatment of pediatric brain tumors—An update. Advanced Drug Delivery Reviews, 185, 114303. https://doi.org/10.1016/j.addr.2022.114303
Ribeiro, A., Fote, G., Himstead, A., Zheng, M., Elliott, E., Smith, S. M., Lou, J., & Yuen, C. A. (2025). Glioblastoma: From pathophysiology to novel therapeutic approaches. Biomedicines, 13(8), 1963. https://doi.org/10.3390/biomedicines13081963
Salman, M. M., Kitchen, P., Halsey, A., Wang, M. X., Törnroth-Horsefield, S., Conner, A. C., Badaut, J., Iliff, J. J., & Bill, R. M. (2022). Emerging roles for dynamic aquaporin-4 subcellular relocalization in CNS water homeostasis. Brain, 145(1), 64–75. https://doi.org/10.1093/brain/awab318
Sarkaria, J. N., Hu, L. S., Parney, I. F., Pafundi, D. H., Brinkmann, D. H., Laack, N. N., Giannini, C., Burns, T. C., Kizilbash, S. H., Laramy, J. K., et al. (2018). Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data. Neuro-Oncology, 20(2), 184–191. https://doi.org/10.1093/neuonc/nox175
Shah, H. A., Mishra, A., Gouzoulis, M. J., Ben-Shalom, N., & D'Amico, R. S. (2022). Analysis of factors leading to early termination in glioblastoma-related clinical trials. Journal of Neuro-Oncology, 158(3), 489–495. https://doi.org/10.1007/s11060-022-04034-3
Sonabend, A. M., Gould, A., Amidei, C., Ward, R., Schmidt, K. A., Zhang, D. Y., Gomez, C., Bebawy, J. F., Liu, B. P., Bouchoux, G., et al. (2023). Repeated blood-brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: A phase 1 trial. The Lancet Oncology, 24(5), 509–522. https://doi.org/10.1016/S1470-2045(23)00112-2
Song, M. G., & Kang, K. W. (2026). Albumin-based drug delivery for glioblastoma treatment: Mechanistic rationale, preclinical evidence, and clinical translation. Cells, 15(13), 1180. https://doi.org/10.3390/cells15131180
Song, Y., & Wang, Y. (2026). Natural and synthetic compounds, swords for glioblastoma therapy: From tumor to its microenvironment. International Journal of Molecular Sciences, 27(17), 7798. https://doi.org/10.3390/ijms27177798
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine, 352(10), 987–996. https://doi.org/10.1056/NEJMoa043330
Stupp, R., Taillibert, S., Kanner, A., Read, W., Steinberg, D. M., Lhermitte, B., Toms, S., Idbaih, A., Ahluwalia, M. S., Fink, K., et al. (2017). Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in glioblastoma: A randomized clinical trial. JAMA, 318(23), 2306–2316. https://doi.org/10.1001/jama.2017.18718
Tang, J., Karbhari, N., & Campian, J. L. (2025). Therapeutic targets in glioblastoma: Molecular pathways, emerging strategies, and future directions. Cells, 14(7), 494. https://doi.org/10.3390/cells14070494
Tashima, T. (2020). Smart strategies for therapeutic agent delivery into brain across the blood-brain barrier using receptor-mediated transcytosis. Chemical and Pharmaceutical Bulletin, 68(4), 316–325. https://doi.org/10.1248/cpb.c19-00842
Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021). Strategies for delivering therapeutics across the blood–brain barrier. Nature Reviews Drug Discovery, 20(5), 362–383. https://doi.org/10.1038/s41573-021-00139-y
Tharamelveliyil Rajendran, A., Dheeraj Rajesh, G., Kumar, P., Shivam Raju Dwivedi, P., Shashidhara Shastry, C., & Narayanan Vadakkepushpakath, A. (2026). Folic acid-guided PLGA-zein core–shell nanoparticles for co-delivery of temozolomide and ellagic acid to overcome PARP-mediated chemoresistance in glioblastoma. Pharmaceutics, 18(6), 655. https://doi.org/10.3390/pharmaceutics18060655
Vaccines. (2026). Nanohydrogel composite vaccine capable of bypassing the blood–brain barrier and targeting tumors for glioblastoma immunotherapy via intranasal immunization. Vaccines, 14(9), 797. https://doi.org/10.3390/vaccines14090797
Woodworth, G. F., Anastasiadis, P., Ozair, A., Chabros, J., Bettegowda, C., Chen, C., Gerstl, J. V. E., Douville, C., Mekary, R. A., Smith, T. R., et al. (2025). Microbubble-enhanced transcranial focused ultrasound with temozolomide for patients with high-grade glioma (BT008NA): A multicentre, open-label, phase 1/2 trial. The Lancet Oncology, 26(12), 1651–1664. https://doi.org/10.1016/S1470-2045(25)00512-8
Yang, H., Ye, Y., Liu, M., & Zhou, X. (2025). Methylstat inhibits glioma cell proliferation by modulating cell cycle regulators via the p53/p21 and JMJD2A/PDK1/AKT/mTOR pathways. Pharmaceuticals, 18(9), 1344. https://doi.org/10.3390/ph18091344
Zheng, Z., Kobayashi, A., & Kitagawa, Y. (2026). Comparison of fluorescent probes for IDH-wildtype glioblastoma, metastatic brain tumors, and PCNSL: A biomechanical perspective. International Journal of Molecular Sciences, 27(10), 4495. https://doi.org/10.3390/ijms27104495
Targeted Nanomedicine for Triple-Negative Breast Cancer Closing the Delivery Efficiency Gap
Unlocking Aromatic Polyketides to Combat Antimicrobial Resistance: A Systematic Review and Meta-Analytic Perspective on Biosynthetic Potential and Synthetic Biology Strategies
Network Pharmacology and Docking-Based Evaluation of Quercetin as an Inhibitor of PI3K Pathway in Glioblastoma